Royalty Pharma PLC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Royalty Pharma plc has announced its 2026 Annual General Meeting of Shareholders will be held on June 4, 2026, and detailed strong financial and strategic execution in 2025, including significant capital deployment and shareholder returns.
NASDAQ
Royalty Pharma plc amends its Membership Interests Purchase Agreement to include a share subscription, allowing sellers to receive Class B ordinary shares in the company.
NASDAQ
Royalty Pharma plans to acquire its external manager, RP Management, LLC, for $200 million in cash and 24,530,266 non-voting shares, aiming to streamline operations and enhance shareholder value.
NASDAQ
Royalty Pharma appoints Vlad Coric, CEO of Biohaven, to its Board of Directors, effective immediately.
NASDAQ
Royalty Pharma executives discussed the recent internalization of its manager, the company's growth prospects, and its pipeline of royalty assets at the TD Cowen Healthcare Conference.
NASDAQ
Royalty Pharma reports positive investor feedback following the J.P. Morgan Conference, highlighting excitement around the internalization of RP Management and the company's capital allocation strategy.
NASDAQ
DEFA14A: Royalty Pharma to Acquire External Manager in $1.1 Billion Deal, Announces $3 Billion Share Buyback
Royalty Pharma plans to internalize its management structure and initiate a substantial share repurchase program, aiming to boost shareholder value.
NASDAQ
Royalty Pharma announces the acquisition of its external manager, RP Management, and provides a corporate update, projecting strong portfolio receipts for 2024 and outlining future capital deployment plans.
NASDAQ
Royalty Pharma plc is set to acquire its external manager, RP Management, LLC, in a move expected to simplify its corporate structure, generate significant cost savings, and enhance shareholder value, alongside a newly approved $3 billion share repurchase program.
NASDAQ
Royalty Pharma PLC has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.
NASDAQ
Royalty Pharma's upcoming Annual General Meeting on June 6, 2024, will address key governance matters, including director elections, executive compensation, and auditor appointments.